Eliopoulos G M
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA.
Drugs. 1999;58 Suppl 2:23-8. doi: 10.2165/00003495-199958002-00005.
Several newer fluoroquinolones, which have been recently introduced or are under investigation, display substantially greater potency against gram-positive organisms than the older generation agents of this class. Nevertheless, for problem organisms including methicillin-resistant strains of Staphylococcus aureus and many Enterococcus faecium, concentrations of newer antimicrobials required to inhibit 90% of organisms in the collections studied remain above those that are projected to be achievable with clinical use. Nevertheless, enhanced potency of several newer quinolones may result in a favourable pharmacodynamic profile leading to improved outcomes against gram-positive infections and possibly to the delayed or diminished emergence of resistance to these agents.
几种最近推出或正在研究的新型氟喹诺酮类药物,对革兰氏阳性菌的抗菌效力比该类的老一代药物显著更强。然而,对于包括耐甲氧西林金黄色葡萄球菌和许多粪肠球菌在内的难治疗病原体,在所研究的菌库中抑制90%的菌株所需的新型抗菌药物浓度仍高于预计临床使用可达到的浓度。尽管如此,几种新型喹诺酮类药物增强的效力可能会产生有利的药效学特征,从而改善革兰氏阳性菌感染的治疗效果,并可能延缓或减少对这些药物耐药性的出现。